A share price of Abbott Laboratories [ABT] is currently trading at $129.93, up 2.07%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ABT shares have gain 2.83% over the last week, with a monthly amount drifted -3.35%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Abbott Laboratories [NYSE: ABT] stock has seen the most recent analyst activity on July 18, 2025, when Jefferies upgraded its rating to a Buy but kept the price target unchanged to $145 for it. Previously, Leerink Partners started tracking the stock with Market Perform rating on June 16, 2025, and set its price target to $143. On October 08, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $130 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $131 on September 19, 2024. Edward Jones downgraded its rating to a Hold. Goldman started tracking with a Buy rating for this stock on May 30, 2024, and assigned it a price target of $121. In a note dated July 21, 2023, Wolfe Research upgraded an Peer Perform rating on this stock.
Abbott Laboratories experienced fluctuations in its stock price throughout the past year between $107.11 and $141.23. Currently, Wall Street analysts expect the stock to reach $147 within the next 12 months. Abbott Laboratories [NYSE: ABT] shares were valued at $129.93 at the most recent close of the market. An investor can expect a potential return of 13.14% based on the average ABT price forecast.
Analyzing the ABT fundamentals
Trailing Twelve Months sales for Abbott Laboratories [NYSE:ABT] were 43.11B which represents 7.37% growth. Gross Profit Margin for this corporation currently stands at 0.56% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.18%, and Net Profit Margin reading is 0.32%. To continue investigating profitability, this company’s Return on Assets is posted at 0.17, Equity is 0.32 and Total Capital is 0.11. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Abbott Laboratories [NYSE:ABT] is 1.82. Also, the Quick Ratio is 1.30, while the Cash Ratio stands at 0.5. Considering the valuation of this stock, the price to sales ratio is 5.25, the price to book ratio is 4.47 and price to earnings (TTM) ratio is 16.25.
Transactions by insiders
Recent insider trading involved Blount Sally E., Director, that happened on Apr 30 ’25 when 2600.0 shares were sold. Director, SALLY E BLOUNT completed a deal on Apr 30 ’25 to buy 2600.0 shares. Meanwhile, EVP AND GROUP PRESIDENT Earnhardt Lisa D sold 91167.0 shares on Mar 06 ’25.
